Condition 1: Acute myocardial infarction. Condition 2: Heart failure. ST elevation (STEMI) myocardial infarction of anterior wall Heart failure
Conditions
Interventions
Intervention 1: Intervention group: In addition to routine treatments, the group receiving squalene drops will receive sublingually and 4 times a day with a dose of 5 drops each time for 5 days. The c
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients 18 to 80 years old Patients who have been diagnosed with ST segment elevation myocardial infarction and have undergone successful vascularization with angioplasty in the vessel related to the infarct. Ejection fraction less than forty percent in the field of acute Myocardial infarction
Exclusion criteria
Exclusion criteria: Ventricular arrhythmia Congenital heart disease Suspected or documented history of heart failure or decreased ejection fraction (EF) of the left ventricle CABG candidate patients or previous CABG history GFR less than 30 People with autoimmune diseases or connective tissue disease People with cancer Pregnant and lactating women Psychiatric patients and people who cannot complete the one-month clinical follow-up during the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ejection fraction. Timepoint: Patients undergo echocardiography in the first 24 hours before starting the drug and then after 30 days. Method of measurement: Echocardiography. | — |
Secondary
| Measure | Time frame |
|---|---|
| Wall motion abnormality. Timepoint: Before starting the medicine and also thirty days after starting the medicine. Method of measurement: Echocardiography.;Diastolic dysfunction. Timepoint: Before starting the medicine and also thirty days after starting the medicine. Method of measurement: Echocardiography.;Pulmonary arterial pressure. Timepoint: Before starting the medicine and also thirty days after starting the medicine. Method of measurement: Echocardiography.;Valvular Dysfunction. Timepoint: Before starting the medicine and also thirty days after starting the medicine. Method of measurement: Echocardiography.;Laboratory factors such as complete blood cell count. Timepoint: Before starting the drug and after thirty days from the start of the drug. Method of measurement: Laboratory kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAlireza fazeli
Mashhad University of Medical Sciences
Outcome results
None listed